Fulcrum Therapeutics Inc (FULC) Directors and Executive Officers

Officers & Directors

Gregory Tourangeau
Vice President, Finance - (Principal Accounting Officer)

Alex C. Sapir
President and Chief Executive Officer

Kate Haviland
Chairman of the Board

Alan Ezekowitz
Director

James J. Collins
Director

Alan Musso
Chief Financial Officer - (Principal Financial Officer)

James Geraghty
Director

Sonja Banks
Director

Katina Dorton
Director

Robert J. Gould
Director,

Fulcrum Therapeutics Inc currently has 55 employees.

News about Fulcrum Therapeutics Inc Key Personnel

Fulcrum Therapeutics’ Phase 3 REACH Trial of Losmapimod Shows No Improvement for FSHD Patients; Financial Challenges Emerge Amid Stock Option Grantsnn,

nnFulcrum Therapeutics Reports Disappointing Phase 3 Results for Losmapimod in FSHD: Financial Ramifications and Stock Performance Analysisnn
Fulcrum Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare genetic disorders, recently disclosed top-line results from its Phase 3 REACH clinical trial assessing the efficacy of losmapimod for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Unfortunately, the trial outcomes fell below expectations, as losmapimod did not demonstrate significant improvement in relative surface area (RSA)—a critical measure of reachable workspace (RWS)—when compared to a placebo at the 48-week mark.
Th...